Fig. 3From: Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studiesPooled analysis of TDI focal score at Week 12 by smoking status (FAS). **P < 0.01 vs placebo. FAS, full analysis set; GLY, glycopyrrolate; LSM, least squares mean; SE, standard error; TDI, transition dyspnea indexBack to article page